ThemenRubriken
MiniRubriken
Die Kommission will die Biotech-Strategie der EU auf Grundlage einer Studie über die Folgen, Möglichkeiten und Herausforderungen, die sich für Europa aus einer modernen Biotechnologie ergeben, noch vor 2007 aktualisieren, um sie mit der Lissabon-Agenda in Übereinstimmung zu bringen.
In January 2002, the Commission adopted a Communication entitled 'Life Sciences and Biotechnology: A Strategy for Europe
'. The strategy consists of specific policy orientations and a 30-point action plan to turn the policy into action. Since the adoption of the European biotechnology strategy, the Commission issues yearly reports on its implementation - the first
progress report was published in March 2003, the second
in April 2004.
The Commission's 3rd progress report
on the European strategy for life sciences and biotechnology states that 2004 seems to have been a year of consolidation rather than growth for European biotechnology. The report highlights some progress since the last report but states that the situation regarding European biotechnology and its competitiveness still needs to be improved, mainly because of:
In the report, the Commission announced that a reflection on the role of life science and biotechnology in the Lisbon Agenda was necessary. Accordingly, the Commission's Joint Research Centre (JRC) launched, on 21 October 2005, a study on the social, economic and environmental consequences and challenges of modern biotechnology. The Council and all stakeholders are invited to participate in this reflection process.
The study aims also to increase public awareness and understanding of life sciences and biotechnology.